Source-grounded facts extracted from BioRestorative Therapies, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Jatinder Dhaliwal was appointed as Director at BioRestorative Therapies, Inc..
“the remaining members of the Company’s Board of Directors (the “Board”) appointed Mika Grasso, Katharyn Field and Jatinder Dhaliwal (collectively, the “New Directors”), designees of the Lender, as directors of the Company.”
Katharyn Field was appointed as Director at BioRestorative Therapies, Inc..
“the remaining members of the Company’s Board of Directors (the “Board”) appointed Mika Grasso, Katharyn Field and Jatinder Dhaliwal (collectively, the “New Directors”), designees of the Lender, as directors of the Company.”
Mika Grasso was appointed as Director at BioRestorative Therapies, Inc..
“the remaining members of the Company’s Board of Directors (the “Board”) appointed Mika Grasso, Katharyn Field and Jatinder Dhaliwal (collectively, the “New Directors”), designees of the Lender, as directors of the Company.”
Patrick F. Williams resigned as Director at BioRestorative Therapies, Inc..
“Effective June 11, 2026, pursuant to the Revolving Loan Agreement, Francisco Silva, Nickolay Kukekov and Patrick F. Williams resigned as directors of the Company.”
Nickolay Kukekov resigned as Director at BioRestorative Therapies, Inc..
“Effective June 11, 2026, pursuant to the Revolving Loan Agreement, Francisco Silva, Nickolay Kukekov and Patrick F. Williams resigned as directors of the Company.”
Francisco Silva resigned as Director at BioRestorative Therapies, Inc..
“Effective June 11, 2026, pursuant to the Revolving Loan Agreement, Francisco Silva, Nickolay Kukekov and Patrick F. Williams resigned as directors of the Company.”
BioRestorative Therapies, Inc. entered into Revolving Loan Agreement with Bowery Group LLC valued at Loans up to $1,000,000 aggregate principal; interest rate 12% per annum; default rate 16% per annum; (effective 2026-06-10).
“On June 10, 2026, BioRestorative Therapies, Inc. (the “Company”) entered into a Revolving Loan Agreement (the “Revolving Loan Agreement”) with Bowery Group LLC (the “Lender”).”
BioRestorative Therapies, Inc. shareholders approved Approval of an amendment to the Company's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 75,000,000 to 1,500,000,000 at the 2026-05-26 meeting.
“1. Approval of an amendment to the Company’s Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 75,000,000 to 1,500,000,000: For 9,868,606 Against 2,389,059 Abstentions 179,207”
BioRestorative Therapies, Inc. entered into Securities Purchase Agreement with certain institutional investors (effective 2026-02-11).
“On February 11, 2026, BioRestorative Therapies, Inc. (the “Company”) commenced a public offering (the “Offering”) of an aggregate of (a) 12,560,715 units (the “Common Units”), consisting of (i) 12,560,715 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) five-year warrants to purchase up to 12,560,715 shares of Common Stock (the “Common Stock Warrants”), at an offering price of $0.35 per Common Unit, and (b) 1,725,000 units (the “Pre-Funded Units”), consisting of (i) pre-funded warrants to purchase up to 1,725,000 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) five-year warrants to purchase up to 1,725,000 shares of Common Stock, at an offering price of $0.3499 per Pre-Funded Unit.”
BioRestorative Therapies, Inc. issued up to an aggregate of 508,592 shares of the Company's common stock of warrant to several investors.
“the Company agreed to issue to the Purchasers unregistered warrants (the “Unregistered Warrants”) to purchase up to an aggregate of 508,592 shares of the Company’s common stock (the “Unregistered Warrant Shares”) at an exercise price of $2.75 per share.”
BioRestorative Therapies, Inc. engaged CBIZ CPAs P.C. as its auditor.
“On April 16, 2025, the Audit Committee of the Company’s Board of Directors engaged CBIZ CPAs P.C. as the Company’s independent registered public accounting firm.”
Marcum LLP resigned as auditor of BioRestorative Therapies, Inc..
“On April 16, 2025, Marcum informed BioRestorative Therapies, Inc. (the “Company”) that Marcum resigned as the Company’s independent registered public accounting firm.”
BioRestorative Therapies, Inc. entered into Agreements with certain holders of its existing warrants valued at approximately $8.1 million (effective 2024-02-06).
“On February 6, 2024, BioRestorative Therapies, Inc. (the “Company”) entered into agreements (the “Agreements”) with certain holders of its existing warrants exercisable for an aggregate of 3,351,580 shares of its common stock (collectively, the “Existing Warrants”), to exercise their warrants at a reduced exercise price of $2.33 per share, in exchange for new warrants (the “New Warrants”) as described below.”
BioRestorative Therapies, Inc. shareholders approved Ratification of the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-09-13 meeting.
“For 2,751,541 Against 15,525 Abstentions 11,070”
BioRestorative Therapies, Inc. shareholders approved Approval of amendment to the Company’s 2021 Stock Incentive Plan to increase authorized shares from 2,500,000 to 3,850,000 at the 2023-09-13 meeting.
“Against 276,247 Abstentions 22,839”
BioRestorative Therapies, Inc. shareholders approved Election of Class III Directors at the 2023-09-13 meeting.
“Number of Shares For Withheld Broker Non-Votes Lance Alstodt 864,671 6,038 1,907,427 Patrick F. Williams 662,099 208,610 1,907,427”
BioRestorative Therapies, Inc. entered into Placement Agency Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2023-07-11).
“the Company entered into a placement agency agreement dated July 11, 2023 (the “Placement Agency Agreement”), with Titan Partners Group LLC, a division of American Capital Partners, LLC”
BioRestorative Therapies, Inc. entered into Purchase Agreement with several institutional buyers and accredited investors valued at approximately $2.1 million (effective 2023-07-11).
“On July 11, 2023, BioRestorative Therapies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with several institutional buyers and accredited investors (the “Purchasers”)”
BioRestorative Therapies, Inc. entered into Sales Agreement with JonesTrading Institutional Services LLC valued at up to $3.7 million (effective 2023-04-14).
“BioRestorative Therapies, Inc. (the “Company”) entered into a Capital On DemandTM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time, through or to the Agent, shares of the Company’s common stock, par value $0.0001 per share, having an aggregate offering price of up to $3.7 million”
BioRestorative Therapies, Inc. shareholders approved Ratification of the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 at the 2022-11-03 meeting.
“6. Ratification of the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022: For 2,636,553 Against 15,926 Abstentions 3,530”
BioRestorative Therapies, Inc. shareholders approved Recommendation, on a non-binding advisory basis, as to frequency of future advisory votes on the Company’s executive compensation at the 2022-11-03 meeting.
“5. Recommendation, on a non-binding advisory basis, as to frequency of future advisory votes on the Company’s executive compensation: Three Years 1,768,754 Two Years 18,440 One Year 171,693 Abstentions 13,276”
BioRestorative Therapies, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s executive officers at the 2022-11-03 meeting.
“4. Approval, on a non-binding advisory basis, of the compensation of the Company’s executive officers: For 1,785,569 Against 169,088 Abstentions 17,506 Broker Non-Votes 683,846”
BioRestorative Therapies, Inc. shareholders approved Authorization of the reincorporation of the Company from the State of Delaware to the State of Nevada at the 2022-11-03 meeting.
“3. Authorization of the reincorporation of the Company from the State of Delaware to the State of Nevada: For 1,954,622 Against 12,382 Abstentions 5,159 Broker Non-Votes 683,846”
BioRestorative Therapies, Inc. shareholders approved Approval of amendments to the Company’s 2021 Stock Incentive Plan at the 2022-11-03 meeting.
“2. Approval of amendments to the Company’s 2021 Stock Incentive Plan: For 1,790,399 Against 163,058 Abstentions 18,706 Broker Non-Votes 683,846”
BioRestorative Therapies, Inc. shareholders approved Election of Class II Directors at the 2022-11-03 meeting.
“1. Election of Class II Directors: Number of Shares For Withheld Broker Non-Votes David Rosa 1,812,382 159,781 683,846 Francisco Silva 1,951,117 21,046 683,846”
David Rosa was elected as Director at BioRestorative Therapies, Inc..
“Effective November 4, 2021, David Rosa was elected a director of the Company.”
Patrick F. Williams was elected as Director at BioRestorative Therapies, Inc..
“Effective November 4, 2021, Patrick F. Williams was elected a director of the Company.”
Robert E. Kristal was appointed as Chief Financial Officer at BioRestorative Therapies, Inc..
“Effective November 4, 2021, Robert E. Kristal, age 54, was appointed Chief Financial Officer of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.